Rucaparib is used to treat certain types of ovarian and prostate cancers, especially in patients with specific genetic mutations. It's used for maintenance treatment of adult patients with BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy. It's also used to treat BRCA-mutated metastatic castration-resistant prostate cancer in patients who have been treated with androgen receptor-directed therapy and taxane-based chemotherapy.
Rucaparib works by blocking enzymes called poly ADP-ribose polymerase (PARP), which are involved in DNA repair. By inhibiting these enzymes, Rucaparib prevents cancer cells from repairing their DNA, leading to cell death. This mechanism is particularly effective in cancer cells with existing DNA repair deficiencies, such as those with BRCA mutations.
The usual daily dose of Rucaparib for adults is 600 mg taken orally twice daily, totaling 1200 mg per day. The doses should be taken approximately 12 hours apart. Rucaparib is not approved for use in children.
Common side effects of Rucaparib include nausea, fatigue, anemia, increased liver enzymes, vomiting, diarrhea, decreased appetite, and thrombocytopenia (low platelet count). Serious adverse effects include myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), which can be fatal.
Key warnings for Rucaparib include the risk of MDS/AML, which can be fatal. Patients should be monitored for hematological toxicity. Rucaparib can also cause fetal harm, so effective contraception is advised for both males and females during treatment. Patients should avoid sun exposure due to photosensitivity risk. There are no specific contraindications listed, but patients should discuss their full medical history with their healthcare provider.
Rucaparib is used to treat certain types of ovarian and prostate cancers, especially in patients with specific genetic mutations. It's used for maintenance treatment of adult patients with BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have responded to platinum-based chemotherapy. It's also used to treat BRCA-mutated metastatic castration-resistant prostate cancer in patients who have been treated with androgen receptor-directed therapy and taxane-based chemotherapy.
Rucaparib works by blocking enzymes called poly ADP-ribose polymerase (PARP), which are involved in DNA repair. By inhibiting these enzymes, Rucaparib prevents cancer cells from repairing their DNA, leading to cell death. This mechanism is particularly effective in cancer cells with existing DNA repair deficiencies, such as those with BRCA mutations.
The usual daily dose of Rucaparib for adults is 600 mg taken orally twice daily, totaling 1200 mg per day. The doses should be taken approximately 12 hours apart. Rucaparib is not approved for use in children.
Common side effects of Rucaparib include nausea, fatigue, anemia, increased liver enzymes, vomiting, diarrhea, decreased appetite, and thrombocytopenia (low platelet count). Serious adverse effects include myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), which can be fatal.
Key warnings for Rucaparib include the risk of MDS/AML, which can be fatal. Patients should be monitored for hematological toxicity. Rucaparib can also cause fetal harm, so effective contraception is advised for both males and females during treatment. Patients should avoid sun exposure due to photosensitivity risk. There are no specific contraindications listed, but patients should discuss their full medical history with their healthcare provider.
.svg)
